An update on the ongoing litigation involving the prescription drug Elmiron including when these cases might settle and what their estimated payout value is.

MAY 2023 Update

As Janssen Pharmaceuticals continues to negotiate confidential settlements for existing Elmiron claims, the influx of new cases into the Elmiron Multi-District Litigation (MDL) has significantly decreased. Over the past 30 days, only three new cases were introduced into the class action lawsuit, bringing the current total to 1,891. This is the smallest increase in new cases since the MDL's establishment.

APRIL 2023 UPDATE

The majority of these lawsuits are expected to settle this year.

SEPTEMBER 2022 UPDATE

The Elmiron class action lawsuit continues to grow. There were 1,740 cases pending in the Elmiron class action MDL and another 169 pending cases in state court in New Jersey.

AUGUST 2022 UPDATE

July ended up being a very slow month for the Elmiron litigation. After seeing record high numbers of new Eliron vision damage cases transferred into the MDL recently, no new cases were added after July 7. A status conference with Judge Martinotti was held on July 13 and resulted in an order regarding appointments to the Plaintiffs’ Steering Committee, but there were no docket entries in the MDL for the rest of the month afterward.

But there is an Elmiron trial coming in January 2022. If these lawsuits get that far. You could see a global settlement before that trial.

WHO ARE THE DEFENDANTS TO PAY A POSSIBLE SETTLEMENT?

Teva Branded Pharmaceutical and related companies, Janssen Pharmaceuticals, and Johnson & Johnson are the defendants. We believe these lawsuits will be mostly resolved in 2023.

WHAT ARE THE ELMIRON LAWSUITS ABOUT?
The Elmiron lawsuits are against the manufacturers of the drug Elmiron, primarily Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Elmiron, also known as pentosan polysulfate sodium (PPS), is a medication prescribed for the treatment of interstitial cystitis (IC), a painful bladder syndrome.

In recent years, numerous patients who have used Elmiron have reported developing vision problems, specifically a unique form of eye damage known as pigmentary maculopathy. There really is no doubt that Elmiron caused this condition. This condition affects the macula, the central part of the retina responsible for sharp, detailed vision. Pigmentary maculopathy can lead to difficulty reading, dark spots in the visual field, and, in some cases, blindness.

Research and case studies have suggested a link between long-term use of Elmiron and the development of pigmentary maculopathy. As a result, patients who have experienced vision problems after taking the drug have filed lawsuits against Janssen Pharmaceuticals. The plaintiffs argue that the company failed to adequately warn patients and healthcare providers about the potential risks associated with Elmiron.

The lawsuits generally seek compensation for medical expenses, lost wages, pain and suffering, and other damages related to the plaintiffs' vision problems. In response to the growing number of lawsuits, the U.S. Judicial Panel on Multidistrict Litigation consolidated federal Elmiron lawsuits into a multidistrict litigation (MDL) in December 2020. This MDL aims to streamline the legal process by allowing the cases to be heard by one judge, which can lead to more consistent rulings and potentially facilitate a global settlement in 2023.

[ Ссылка ]

There are now over 700 Elmiron eye damage cases in the MDL and the first bellwether trials are set for January 2023.

свернуть